Stock analysts at Lifesci Capital assumed coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. The brokerage set an "outperform" rating and a $19.00 price target on the stock. Lifesci Capital's price objective would indicate a potential upside of 203.03% from the company's previous close. Lifesci Capital also issued estimates for Monte Rosa Therapeutics' Q4 2024 earnings at ($0.66) EPS and FY2024 earnings at ($2.00) EPS.
Separately, Wells Fargo & Company cut Monte Rosa Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $14.00 to $11.00 in a report on Thursday, December 19th.
Get Our Latest Stock Analysis on Monte Rosa Therapeutics
Monte Rosa Therapeutics Stock Up 1.0 %
Monte Rosa Therapeutics stock traded up $0.06 during trading hours on Wednesday, hitting $6.27. The stock had a trading volume of 544,310 shares, compared to its average volume of 674,521. Monte Rosa Therapeutics has a fifty-two week low of $3.21 and a fifty-two week high of $12.40. The company has a 50-day moving average of $6.14 and a two-hundred day moving average of $6.76. The company has a market cap of $385.21 million, a PE ratio of -3.43 and a beta of 1.50.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC bought a new position in shares of Monte Rosa Therapeutics in the 4th quarter worth $220,000. Two Sigma Advisers LP bought a new position in shares of Monte Rosa Therapeutics in the 4th quarter worth $180,000. Two Sigma Investments LP boosted its position in shares of Monte Rosa Therapeutics by 1,965.1% in the 4th quarter. Two Sigma Investments LP now owns 278,785 shares of the company's stock worth $1,935,000 after purchasing an additional 265,285 shares during the last quarter. Rafferty Asset Management LLC bought a new position in shares of Monte Rosa Therapeutics in the 4th quarter worth $192,000. Finally, ProShare Advisors LLC bought a new position in shares of Monte Rosa Therapeutics in the 4th quarter worth $101,000. 79.96% of the stock is currently owned by institutional investors.
Monte Rosa Therapeutics Company Profile
(
Get Free Report)
Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.
Featured Articles
Before you consider Monte Rosa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.
While Monte Rosa Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
